Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on April 22, 2020, covering events occurring on April 16, 2020, and April 20, 2020. The filing primarily addresses changes to the composition of the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
- Director Resignations: On April 16, 2020, Jane F. Barlow, M.D., M.B.A, M.P.H. and Robert V. LaPenta, Jr. resigned from the Board of Directors and all associated committees. The Company stated these resignations were not the result of any disagreement with the Company.
- Director Appointment: On April 16, 2020, the Board appointed Karen L. Ling to fill one of the vacancies. Ms. Ling is considered independent under Nasdaq rules and will serve until the 2020 Annual Meeting of Stockholders.
- Board Size Reduction: Following the appointment of Ms. Ling, the Board reduced the number of authorized directors from 11 to nine.
- Audit Committee Changes: On April 20, 2020, Angus C. Russell was appointed Chairperson of the Audit Committee, and Paul M. Bisaro was appointed as a member to fill vacancies left by Mr. LaPenta, Jr.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. It notes that Ms. Ling will receive compensation consistent with other non-employee directors as described in the 2019 Proxy Statement. No material transactions involving Ms. Ling exceeding $120,000 were disclosed.
Investor Verification Checklist
- Verify the independence status of the newly appointed director, Karen L. Ling, per Nasdaq Global Select Market rules.
- Confirm the effective dates of the resignations and appointments (April 16 and April 20, 2020).
- Review the 2019 Definitive Proxy Statement for details on director compensation structures applicable to Ms. Ling.
- Check for any subsequent filings regarding the election of permanent directors at the 2020 Annual Meeting of Stockholders.